178 related articles for article (PubMed ID: 23877872)
1. Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients?
Kilic L; Ordu C; Ekenel M; Yildiz I; Keskin S; Sen F; Gural Z; Asoglu O; Kizir A; Aykan F
Med Oncol; 2013; 30(3):660. PubMed ID: 23877872
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer.
Ustaalioglu BBO; Bilici A; Tilki M; Surmelioglu A; Erkol B; Figen M; Uyar S
J Cancer Res Ther; 2018 Sep; 14(Supplement):S736-S741. PubMed ID: 30249896
[TBL] [Abstract][Full Text] [Related]
3. D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy.
Peng J; Wei Y; Zhou F; Dai J; Zhong Y; Xie C; Qin Y; Gong J; Xiong B; Zhou Y
Cancer Med; 2016 Oct; 5(10):2773-2780. PubMed ID: 27666138
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection.
Wang X; Shen Y; Zhu H; Zhao Y; Li Z; Qiu M; Li Q; Gou H; Yang Y; Cao D; Liu J; Yi C; Liao Z; Luo D; Bi F; Xu F
Gastric Cancer; 2016 Jan; 19(1):245-54. PubMed ID: 25609451
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Lee J; Lim DH; Kim S; Park SH; Park JO; Park YS; Lim HY; Choi MG; Sohn TS; Noh JH; Bae JM; Ahn YC; Sohn I; Jung SH; Park CK; Kim KM; Kang WK
J Clin Oncol; 2012 Jan; 30(3):268-73. PubMed ID: 22184384
[TBL] [Abstract][Full Text] [Related]
7. Identification of patients with lymph node metastasis from gastric cancer who may benefit from adjuvant chemoradiotherapy after D2 dissection--do N3 patients benefit from additional radiation?
Fan M; Li G; Shen L; Zhang H; Liang L; Zhang Z
Br J Radiol; 2016; 89(1059):20150758. PubMed ID: 26728420
[TBL] [Abstract][Full Text] [Related]
8. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
Dikken JL; Jansen EP; Cats A; Bakker B; Hartgrink HH; Kranenbarg EM; Boot H; Putter H; Peeters KC; van de Velde CJ; Verheij M
J Clin Oncol; 2010 May; 28(14):2430-6. PubMed ID: 20368551
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma.
Leong CN; Chung HT; Lee KM; Shakespeare TP; Mukherjee RK; Wong LC; Lu JJ; Tey J; Lim R; So JB; Back MF
Cancer J; 2008; 14(4):269-75. PubMed ID: 18677137
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
Shin K; Park SJ; Lee J; Park CH; Song KY; Lee HH; Seo HS; Jung YJ; Park JM; Lee SH; Roh SY; Kim IH
BMC Cancer; 2019 Dec; 19(1):1232. PubMed ID: 31852475
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemoradiation versus chemotherapy for stage III gastric cancer after surgery with curative intent.
Turanli S; Atalay C; Berberoglu U; Gulben K
J Cancer Res Ther; 2015; 11(2):369-74. PubMed ID: 26148602
[TBL] [Abstract][Full Text] [Related]
12. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK
J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study.
Kim IH; Park SS; Lee CM; Kim MC; Kwon IK; Min JS; Kim HI; Lee HH; Lee SI; Chae H
Ann Surg Oncol; 2018 May; 25(5):1176-1183. PubMed ID: 29450755
[TBL] [Abstract][Full Text] [Related]
14. Age as a modifier of the effects of chemoradiotherapy with infusional 5-fluorouracil after D2 dissection in gastric cancer.
Wu HC; Lin WL; Lin CL; Lin CY; Chen SW; Chen YX; Chen CH; Lee SW; Chen SH; Tsao CJ; Huang WT; Guo HR
Aging (Albany NY); 2021 Jul; 13(13):17337-17348. PubMed ID: 34226296
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant radiotherapy for gastric carcinoma: 10 years follow-up of 244 cases from a single institution.
Misirlioglu HC; Coskun-Breuneval M; Kucukpilakci B; Ugur VI; Elgin Y; Demirkasimoglu T; Kara SP; Ozgen A; Sanri E; Guney Y
Asian Pac J Cancer Prev; 2014; 15(20):8871-6. PubMed ID: 25374221
[TBL] [Abstract][Full Text] [Related]
16. Prognostic analysis of patients with operable gastric cancer and tolerability to adjuvant radio-chemo-therapy.
Kucukoner M; Arpaci E; Isikdogan A; Bilici M; Uncu D; Cetin B; Dane F; Inanc M; Ekinci AS; Inal A; Cayir K; Yetisyigit T; Ozdemir N; Kaplan MA; Aksoy S; Alkıs N; Tekin SB; Eroglu C; Turhal S; Buyukberber S
Neoplasma; 2013; 60(1):19-25. PubMed ID: 23067212
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis.
He Q; Ma L; Li Y; Li G
BMC Gastroenterol; 2016 Jan; 16():8. PubMed ID: 26782354
[TBL] [Abstract][Full Text] [Related]
18. Intraoperative radiotherapy combined with adjuvant chemoradiotherapy for locally advanced gastric adenocarcinoma.
Fu S; Lu JJ; Zhang Q; Yang Z; Peng L; Xiong F
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1488-94. PubMed ID: 18538489
[TBL] [Abstract][Full Text] [Related]
19. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.
Kim S; Lim DH; Lee J; Kang WK; MacDonald JS; Park CH; Park SH; Lee SH; Kim K; Park JO; Kim WS; Jung CW; Park YS; Im YH; Sohn TS; Noh JH; Heo JS; Kim YI; Park CK; Park K
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1279-85. PubMed ID: 16099596
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemoradiation in gastric cancer: long-term outcomes and prognostic factors from a single institution.
Bruixola G; Segura Á; Díaz-Beveridge R; Caballero J; Bennis MH; Palomar L; Giménez A; Mingol F; García-Mora C; Aparicio J
Tumori; 2015; 101(5):517-23. PubMed ID: 26045120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]